Laragh's lessons in pathophysiology and clinical pearls for treating hypertension.
Laragh
J
J
j.sealey@mail.med.cornell.edu
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects; D002309:Cardiology / Q000193:education*; D004095:Dihydropyridines / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004502:Education, Medical, Continuing; D006331:Heart Diseases / Q000209:etiology / Q000628:therapy; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D009599:Nitroprusside / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D012084:Renin-Angiotensin System / Q000502:physiology; D014661:Vasoconstriction / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009599:Nitroprusside; C038806:1,4-dihydropyridine; D012083:Renin